Résumé
Objective::To observe the clinical efficacy of modified Shenling Baizhusan on stroke-associated pneumonia (SAP) with lung-Qi deficiency syndrome and its regulatory effect on inflammatory factors and immune function. Method::One hundred and ten patients were randomly divided into control group (55 cases) and observation group (55 cases) by random number table. Patients in control group got piperacillin sodium and tazobactam sodium for slow intravenous injection, 4.5 g/time, 3 times/days, for 7-10 days, and new antibiotic was chose by drug outcomes, ambroxol hydrochloride injection for low intravenous infusion, 30 mg/time, 2 times/days, for 10 days, and nutritional support and symptomatic comprehensive treatment. In addition to the therapy in control group, patients in observation group were added with modified Shenling Baizhusan, 1 dose/day, for 10 days. And scores of pulmonary infection (CPIS), time of CPIS<6 time of disappearance of cough, time of recovery of temperature, time of recovery of leukocyte, and time of disappearance of lung rales were recorded. And before and after treatment, lung-Qi deficiency syndromes were scored, and levels of procalcitonin (PCT), γ-interferon (IFN-γ), tumor necrosis factor-α (TNF-α), high-sensitivity C-reactive protein (hs-CRP), immunoglobulin A (IgA), immunoglobulin G (IgG), immunoglobulin M (IgM), T Lymphocyte subsets (CD4+, CD8+ and CD4+ /CD8+) were all detected. Result::By rank sum test, the clinical effect in control group was better than that in control group (Z=2.106, P<0.05). Scores of CPIS and lung-Qi deficiency syndromes were lower than those in control group (P<0.01). And time of CPIS<6, time of disappearance of cough, time of recovery of temperature, time of recovery of leukocyte, and time of disappearance of lung moist rales were all shorter than those in control group (P<0.01). And levels of PCT, TNF-α, hs-CRP and CD8+ were lower than those in control group (P<0.01, P<0.05), while levels of IFN-γ, IgA, IgM, CD4+ and CD4+ /CD8+ were all higher than those in control group (P<0.01, P<0.05). Conclusion::In addition to the comprehensive anti-infection therapy, modified Shenling Baizhusan can control the degree of illness, alleviate symptoms, regulate the expressions of inflammatory factors, increase the immune function of the body, and improve the comprehensive efficacy.
Résumé
Objective:To observe influence of dialectical addition and subtraction of Shengmaiyin combined with Xuefu Zhuyu Tang on fibrinolytic activity and coagulation active factor of patients with non-small cell lung cancer at hypercoagulable state. Method:One hundred and eighty patients were randomly divided into control group (58 cases) and observation group (60 cases) by random number table. Patients in control group got low molecular weight heparins calcium injection by subcutaneous injection for 3 weeks, 1.0 mL (5 000 AXa unit)/time, 1 time/day, and oral aspirin enteric-coated tablets, 100 mg/time, 1 time/day. Patients in observation group got dialectical addition and subtraction of Shengmaiyin combined with Xuefu Zhuyu Tang, 1 dose/day. A course of treatment was 8 weeks. And activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), platelet (PLT), fibrinogen (FIB), D-dimer (D-D), plasma tissue plasminogen activator (t-PA), plasminogen activator inhibitor in plasma-1 (PAI-1), von willebrand factor (vWF), P-selectin, basic fibroblast growth factor (bFGF), transforming growth factor (TGF), vascular endothelial growth factor (VEGF) were detected. And before and after treatment, scores of Qi deficiency and blood stasis syndrome and hemorheological indices were detected. Result:After treatment, APTT, PT and TT in observation group were longer than those in control group. Levels of PLT, D-D and PAI-1 were lower than those in control group (PPPPPPPConclusion:Dialectical addition and subtraction of Shengmaiyin combined with Xuefu Zhuyu Tang can ameliorate hypercoagulable state of NSCLC, relieve clinical symptoms, and can regulate fibrinolytic activity and coagulation activity factors, so it can mitigate dangers caused by deep venous thrombosis of NSCLC.